Literature DB >> 3729510

Cutaneous myxomas. A major component of the complex of myxomas, spotty pigmentation, and endocrine overactivity.

J A Carney, J T Headington, W P Su.   

Abstract

Cutaneous myxoma(s) occurred in 22 (54%) of 41 patients with the complex of myxomas, spotty pigmentation, and endocrine overactivity. Of the 16 patients who had cardiac myxoma(s), the cutaneous tumor(s) was (were) detected in 13 (81%) of them prior to diagnosis of the cardiac neoplasm. Thus, the cutaneous tumor may herald a potentially fatal cardiac neoplasm (and other important conditions as well). Clinical features of the lesion were as follows: early appearance (mean age, 18 years); multicentricity (71% of patients); small size (usually less than 1 cm in diameter); widespread distribution but with predilection for certain sites (eyelids, ears, nipples); and tendency for recurrence. Pathologic features included the following: location in dermis, subcutis, or both; sharp circumscription (sometimes encapsulation); hypocellularity; abundant myxoid stroma; prominent capillaries; lobulation (larger lesions); and occasional presence of an epithelial component.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729510     DOI: 10.1001/archderm.122.7.790

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  19 in total

1.  Virilizing ovarian stromal tumor in a young woman with Carney complex.

Authors:  J Aidan Carney; Constantine A Stratakis
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

Review 2.  Autosomal dominant transmission of the NAME syndrome (nevi, atrial myxoma, mucinosis of the skin and endocrine overactivity).

Authors:  R J Koopman; R Happle
Journal:  Hum Genet       Date:  1991-01       Impact factor: 4.132

Review 3.  Carney complex: an update.

Authors:  Ricardo Correa; Paraskevi Salpea; Constantine A Stratakis
Journal:  Eur J Endocrinol       Date:  2015-06-30       Impact factor: 6.664

4.  mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD).

Authors:  Cyrille de Joussineau; Isabelle Sahut-Barnola; Frédérique Tissier; Typhanie Dumontet; Coralie Drelon; Marie Batisse-Lignier; Igor Tauveron; Jean-Christophe Pointud; Anne-Marie Lefrançois-Martinez; Constantine A Stratakis; Jérôme Bertherat; Pierre Val; Antoine Martinez
Journal:  Hum Mol Genet       Date:  2014-05-27       Impact factor: 6.150

Review 5.  More than just skin deep: faciocutaneous clues to genetic syndromes with malignancies.

Authors:  Zhu Shen; Jodi D Hoffman; Fei Hao; Eric Pier
Journal:  Oncologist       Date:  2012-06-15

6.  Novel Mutation in PRKAR1A in Carney Complex.

Authors:  Ko Un Park; Hyun-Sook Kim; Seung Kwan Lee; Woon-Won Jung; Yong-Koo Park
Journal:  Korean J Pathol       Date:  2012-12-26

7.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

Authors:  Maria Cristina Digilio; Emanuela Conti; Anna Sarkozy; Rita Mingarelli; Tania Dottorini; Bruno Marino; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

Review 8.  Carney complex and lentiginosis.

Authors:  Anelia Horvath; Constantine A Stratakis
Journal:  Pigment Cell Melanoma Res       Date:  2009-07-24       Impact factor: 4.693

9.  [Carney complex. Clinical, pathological and genetic features in two generations of a family].

Authors:  D Rothacker; C Kerber
Journal:  Pathologe       Date:  2008-07       Impact factor: 1.011

10.  Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2.

Authors:  C A Stratakis; J A Carney; J P Lin; D A Papanicolaou; M Karl; D L Kastner; E Pras; G P Chrousos
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.